{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:52:21Z","timestamp":1758703941889},"reference-count":58,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) may be 1 of the few cancers for which multiple chemotherapy and nonchemotherapy regimens are considered as standard. Despite the significant activity of chemotherapy in the first-line setting and beyond, its limitations are reflected in the relatively poor ultimate outcomes of patients with MCL treated in the real world. Patients with highly proliferative MCL and those with TP53 mutations tend to respond poorly despite intensive cytotoxic therapies. Patients with comorbidities and those who are geographically isolated may not have access to the regimens that may appear most promising in clinical trials. Thoughtfully directed, nonchemotherapy agents might overcome some of the factors associated with a poor prognosis, such at TP53 mutation, and might resolve some of the challenges related to the toxicity and deliverability of standard chemotherapy regimens. Several clinical trials have already demonstrated that combinations of nonchemotherapy plus chemotherapy drugs can impact outcomes, whereas data with nonchemotherapy agents alone or in combination have suggested that some patients might be well suited to treatment without chemotherapy at all. However, challenges including chronic or unexpected toxicities, the rational vs practical development of combinations, and the financial acceptability of new strategies abound. The nonchemotherapy era is here: how it unfolds will depend on how we meet these challenges.<\/jats:p>","DOI":"10.1182\/blood-2017-05-737510","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T01:05:17Z","timestamp":1505264717000},"page":"1881-1888","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["The potential for chemotherapy-free strategies in mantle cell lymphoma"],"prefix":"10.1182","volume":"130","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine and New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111903445235900_B1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111903445235900_B2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111903445235900_B3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111903445235900_B4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: a population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann Hematol"},{"issue":"22","key":"2019111903445235900_B5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1112.1112","article-title":"Mantle cell lymphoma management and outcome in the U.K\u2019s population-based Haematological Malignancy Research Network [abstract]","volume":"128","author":"Patmore","year":"2016","journal-title":"Blood"},{"issue":"10044","key":"2019111903445235900_B6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2019111903445235900_B7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/leu.2016.305","article-title":"Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499","volume":"31","author":"Smith","year":"2017","journal-title":"Leukemia"},{"key":"2019111903445235900_B8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study [abstract]","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111903445235900_B9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1172\/JCI1348","article-title":"Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice","volume":"101","author":"Proietti","year":"1998","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111903445235900_B10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"2019111903445235900_B11","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"2019111903445235900_B12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111903445235900_B13","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111903445235900_B14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111903445235900_B15","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903445235900_B16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"2019111903445235900_B17","author":"Rule"},{"issue":"2","key":"2019111903445235900_B18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111903445235900_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1095.1095","article-title":"Targeted sequencing of diagnostic samples correlated to clinical outcome: data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) studies with long-term follow-up [abstract]","volume":"128","author":"Eskelund","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111903445235900_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.336.336","article-title":"A molecular model for the prediction of progression free survival in young mantle cell lymphoma patients treated with cytarabine-based high dose sequential chemotherapy and autologous stem cell transplantation: results from the MCL0208 phase III trial from Fondazione Italiana Linfomi (FIL) [abstract]","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111903445235900_B21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clml.2014.12.012","article-title":"Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma","volume":"15","author":"Cohen","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"2019111903445235900_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.148.148","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial [abstract]","volume":"128","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111903445235900_B23","article-title":"Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial [abstract]","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2019111903445235900_B24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903445235900_B25","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2019111903445235900_B26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"2019111903445235900_B27","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"2019111903445235900_B28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111903445235900_B29","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"2019111903445235900_B30","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"16","key":"2019111903445235900_B31","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2019111903445235900_B32","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv216","article-title":"The imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2019111903445235900_B33","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903445235900_B34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111903445235900_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2977.2977","article-title":"Temsirolimus in combination with bendamustine and rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final phase I\/II results [abstract]","volume":"128","author":"Hess","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111903445235900_B36","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.3324\/haematol.2016.154211","article-title":"Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi","volume":"102","author":"Zaja","year":"2017","journal-title":"Haematologica"},{"issue":"10020","key":"2019111903445235900_B37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2019111903445235900_B38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"2019111903445235900_B39","author":"Chiron"},{"issue":"23","key":"2019111903445235900_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.707.707","article-title":"Developing novel therapeutic strategies to overcome ibrutinib resistance in mantle cell lymphoma [abstract]","volume":"126","author":"Pham","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111903445235900_B41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2958.2958","article-title":"Initial report of a multi-institution phase I\/Ib study of ibrutinib with venetoclax in relapsed or refractory mantle cell lymphoma [abstract]","volume":"128","author":"Portell","year":"2016","journal-title":"Blood"},{"key":"2019111903445235900_B42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7548","article-title":"The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed\/refractory mantle cell lymphoma: preliminary results of the phase II AIM study [abstract]","author":"Tam","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903445235900_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.150.150","article-title":"A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma [abstract]","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"2019111903445235900_B44","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111903445235900_B45","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC","volume":"51","author":"Tessoulin","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111903445235900_B46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903445235900_B47","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO)","volume":"93","author":"Kr\u00fcger","year":"2014","journal-title":"Ann Hematol"},{"issue":"16","key":"2019111903445235900_B48","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"355","key":"2019111903445235900_B49","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"23","key":"2019111903445235900_B50","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111903445235900_B51","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111903445235900_B52","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111903445235900_B53","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.18_suppl.2","article-title":"Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract]","volume":"27","author":"Schuster","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7647","key":"2019111903445235900_B54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"30","key":"2019111903445235900_B55","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111903445235900_B56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"29","key":"2019111903445235900_B57","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903445235900_B58","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/17\/1881\/1402889\/blood737510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/17\/1881\/1402889\/blood737510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T08:45:49Z","timestamp":1574153149000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/17\/1881\/36503\/The-potential-for-chemotherapyfree-strategies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":58,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-05-737510","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}